G.B. Frisoni

Discipline

Psychologie (18) Sociologie (1)

Type de document

Articles (28) Recensions (4)

Co-auteur

Date

Source

Mot-clé

Alzheimer's disease (21) Human beings (19) Amyloid (14) Dementia (14) maladie (13) biomarqueur (13) Patients (13) Memory (13) Biochemical markers (13) Mild cognitive impairment (13) Patients (13) maladie (13) Performance (11) Brain (11) Performance (11) cerveau (11) âge (10) Proteins (10) Cognition (10) Age (10) Age (10) plasma (10) information (9) Diagnosis (9) Apolipoprotein E (9) cohorte (9) risque (8) Risk (8) Diagnosis (8) pathologie (7)

Documents écrit par G.B. Frisoni (28) | parle de G.B. Frisoni (0)

Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease.
T. Naccache et al.
Microstructural alterations in the locus coeruleus-entorhinal cortex pathway in Alzheimer's disease and frontotemporal dementia.
G. Quattrini et al. (2024)
Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning.
A. Neumann et al. (4 oct. 2023)
Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN-derived networks and highlights causal links in Alzheimer's disease.
L. Shi et al.
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial.
D. Altomare et al. (1 juin 2023)
The Two-Way Route between Delirium Disorder and Dementia: Insights from COVID-19.
G. Bommarito et al.
Dementia prevention in memory clinics: recommendations from the European task force for brain health services.
G.B. Frisoni et al.
Musical and psychomotor interventions for cognitive, sensorimotor, and cerebral decline in patients with Mild Cognitive Impairment (COPE): a study protocol for a multicentric randomized controlled study.
C.E. James et al. (6 févr. 2023)
Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline.
C. Caprioglio et al. (3 janv. 2023)
Predicting AT(N) pathologies in Alzheimer's disease from blood-based proteomic data using neural networks.
Y. Zhang et al. (2022)
The Biological Substrate of the Motoric Cognitive Risk Syndrome: A Pilot Study Using Amyloid-/Tau-PET and MR Imaging.
G. Bommarito et al. (2022)
The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey.
C. Caprioglio et al. (2022)
Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe.
M. Boccardi et al.
Le Registre suisse pour la santé du cerveau - Une infrastructure nationale pour la recherche sur la maladie d’Alzheimer [The Swiss Brain Health Registry : a national infrastructure for Alzheimer's research]
M. Boillat et al. (15 déc. 2021)
Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort.
J. Xu et al. (3 nov. 2021)
Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services-part 1 of 6.
D. Altomare et al. (11 oct. 2021)
Protocols for cognitive enhancement. A user manual for Brain Health Services-part 5 of 6.
A. Brioschi Guevara et al. (11 oct. 2021)
Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison.
D. Altomare et al.
Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design.
F. Ribaldi et al. (25 mai 2021)
Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies.
L. Shi et al. (2021)
Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology.
L. Shi et al. (2020)
Medical Informatics Platform (MIP): A Pilot Study Across Clinical Italian Cohorts.
A. Redolfi et al. (2020)
Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort.
S. Westwood et al. (2020)
Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay.
L. Shi et al.
Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.
M. Kim et al.

next